In Korea, Novo Nordisk has obtained the license for Saxenda, Wegovy, and Ozempic but only Saxenda is currently on the market
Read Natalies Story Who Can Benefit Individuals who are overweight or obese and have struggled to lose weight through diet and exercise Patients with pre-diabetes, insulin resistance or type 2 diabetes Those experiencing weight-related conditions, such as high blood pressure, elevated cholesterol, fatty liver disease, cardiovascular disease and sleep apnea Individuals seeking a physician-guided, holistic weight-loss plan GLP-1 therapy may not be suitable for everyone, including individuals with certain thyroid, pancreatic or gastrointestinal conditions
Learn more: What is Rybelsus
Cardiovascular and metabolic benefits of extra virgin olive oil phenolic compounds
Ann Nutr Metab (2013) 63:19
Enhance the effect of Vitamin C and E, amplifying your antioxidant defense